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ABSTRACT 
Characterization of Variant Forms of 
Organophosphorus Hydrolase. (April 2003) 
Claire E. Rowe 
Department of Biochemistry and Biophysics 
Texas A&M University 
Fellows Advisor: Dr. James R. Wild 
Department of Biochemistry and Biophysics 
Organophosphorus hydrolase (OPH) is an enzyme capable of degrading 
toxic organophosphorus chemicals including the chemical warfare agents, sarin and 
VX, as well as many insecticides. This project seeks to understand how structure 
contributes to the enzyme's activity and stability by identifying regions of the enzyme 
necessary for each. PCR mutagenesis was used to create 67 variant forms of the 
gene that encodes OPH. Eight variant genes were then sequenced to locate the 
mutations in the enzymes' structure. Two of the eight variants contained only silent 
mutations and expressed wild-type OPH protein. The mutations made in two of the 
variants prevented the protein from being expressed. Characterization of the 
enzymes relative to two substrates, paraoxon and demeton-S, indicated that six 
variants had severely decreased activity. Five of these variants contained mutations 
in regions that have previously been shown to affect the enzyme's activity. Only 
one variant, 12, contained a mutation in a novel region of the enzyme. 
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INTRODUCTION 
In March of 1995, the Aum Shinrikyo cult released sarin in the Tokyo subway 
system killing 11 people and injuring nearly 3, 800 others'. This attack highlighted 
the danger of chemical weapons and the n~ to develop technology to detect and 
decontaminate them. Sarin is a member of the organophosphorus family of 
neurotoxins, which irreversibly inhibit acetylcholinesterase . In addition to being 
used as chemical warfare agents, organophosphorus compounds are also used as 
agricultural pesticides and herbicides. The use of organophosphorus compounds 
as pesticides has increased crop yields and decreased the incidence of insect borne 
disease. However, in 2001 their toxic effects caused 68 cases of life-threatening 
poisoning in United States ~. Organophosphorus compounds pose a major threat to 
human health and safety through both terrorism and accidental abuse. 
Given the dangerous nature of organophosphorus compounds, finding ways 
to detoxify them is of vital importance to public health and safety. The toxicity of 
organophosphorus compounds is due to the reactive nature of their phosphoiyl 
center. Organophosphorus compounds can be detoxified by breaking the bond 
between the phosphoryl center and the leaving group through a hydrolysis reaction. 
Enzymes from a variety of sources have been shown to degrade organophosphorus 
compounds. One of these enzymes, organophosphorus hydrolase (OPH), has been 
isolated from plasmids of Pseudomonas diminuta and Flavobacterium sp. . OPH 
has been the subject of a great deal of research. Its gene, opd, has been 
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sequenced and plasmids have been constructed to allow its expression in a variety 
of biological systems including E. coli. Using the E. coli expression system, more 
than 20 mg of purified protein can be recovered per liter of culture . 
OPH is well suited for a variety of practical applications for a several reasons. 
The enzyme can be produced in large quantities and is relatively stable. OPH is 
capable of degrading a wide range of organophosphorus compounds including 
many pesticides and chemical weapons (Figure 1). OPH is the only 
organophosphorus degrading enzyme that has been shown to detoxify compounds 
containing P-S bonds, such as VX, a very potent chemical warfare agent . 
CH~CH20 ~ y y NO2 
OCH~CH3 
Paraoxon 
CH3CH~O — P S — CHtCH~ S-CH2CH~ 
OCH~CH3 
DemetonS 
CH3 
H — C — 0 — — F 
Sarin 
~CH 
CH3CH20 — P — S — CHtCH2 N 
OCH2CH3 CH 
c 
VX CH 
Figure 1: Substrates of Organophosphorus Hydrolase 
There are many practical applications for the OPH enzyme. OPH could be 
used to detoxify concentrated stockpiles of organophosphorus chemicals. It could 
also be used as a sensor to detect low levels of organophosphorus compounds. 
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Medical applications of OPH are also being developed. For example, injections of 
red blood cells containing OPH could be used to treat people exposed to pesticides 
or chemical warfare agents . Using modified enzymes, which have increased 
affinity for important organophosphorus substrates, could improve the usefulness of 
these technologies. 
Although OPH is an extremely stable enzyme with broad substrate specificity 
it will be necessary to improve the enzyme's characteristics in order to use it in 
many practical applications. The first step in improving the enzyme is to understand 
how the natural enzyme functions. To better understand the source of the enzyme's 
stability, studies of the structure and folding of OPH have been conducted in the 
laboratory of Dr. J. R. Wild'. In these projects, mutations have been made to regions 
of the enzyme known to be important to catalytic activity or structure. In the project 
reported here, the function of other regions of the enzyme was probed by making 
random mutations throughout the enzyme. The goal of the project is to identify new 
regions that are important to enzyme function. By examining the effect of mutations 
on the activity of the enzyme, new insight into the enzyme's structure can be 
obtained. 
METHODS 
PCR Mutagenesis: 
The mutagenesis reactions were preformed using the Diversify PCR Random 
Mutagenesis Kit (Clonetech). The forward PCR primer, 5' AAC AGC TAT GAC CAT 
GAT TA 3', anneals at-102 bp in the opd pUC19 plasmid. The reverse primer, 5' 
TTG TAA AAC GAC GGC CAG GT 3', anneals 38 bp downstream from the stop 
codon. Buffer condition 3 (Table 1), which is designed to produce 3 base pair 
changes per 1, 000 bases, was used. 
Component 
Water 
10 x Taq Buffer 
MnSO, (8 mM) 
dGTP (2 mM) 
50 x Diversify dNTP mix 
Forward Primer 
(1 x10 )Lmol) 
Reverse Primer 
(1 x10 pmol) 
Template DNA (1 ng) 
Taq 
Volume (pL) 
36. 5 
5. 0 
2. 0 
1. 0 
1. 0 
1. 25 
1. 25 
1. 0 
1. 0 
Table 1: PCR Mutagenesis Reaction Buffer Conditions 
Modifications were made to the recommended PCR program in order to 
obtain an adequate amount of product. The PCR primers designed for the opd 
gene did not have a high enough T to work with the PCR protocol recommended 
by the kit's manufacturer. Instead, the program shown in Figure 2 was used. 
PCR Program 
30 X 
95' C 95' C 72' C 
5 min 1 min 
Denaturation 
55' C 
1 min 
Annealing 
1 min 
Extension 4' C 
Hold 
Figure 2: Mutagenesis PCR Program 
Cloning and Transformation: 
pUC19 plasmid (Invitrogen) was used to clone the variant opd genes. Both 
the vector and the PCR product were digested with Hindlll and BamHI. Following 
digestion, the vector fragment and PCR product were gel purified. A five to one 
ratio of insert to vector molecules was used in the ligation reaction. The amount of 
vector and insert DNA needed to achieve this ratio was calculated using the 
following equation. 
Lengthof thelnsert 5 ng InsertNeeded 
LengthoftheVector 1 ngVectorNeeded 
The ligation reaction was performed according to the manufacturer's protocol 
and allowed to proceed overnight at 16 C. Competent DH5a E. coli cells were 
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transformed with 1 irL of the resulting ligation mixture. The cells were plated on LB 
plates that contained 50 pg/mL ampicillin and grown overnight at 37' C. The 
resulting colonies were then replica plated on to two LB" ' plates and glycerol 
stocks were made for long term storage. 
The variants were originally named WTRM or Wild Type Random Mutants 
because they were variants based on the wild type opd gene. They were assigned 
numbers based on their position in the grid on the replica plates. 
Sequencing 
Plasmid DNA for sequencing reactions was prepared using Quiagen's 
QIAprep Spin Miniprep Kit. Cells were grown in 5 mL LB cultures containing 50 
mg/mL ampicillin overnight at 37' C. The reaction conditions used for the 
sequencing reactions are given in Table 2. Four primers were used to sequence the 
entire opd gene, AA98, AA194, AA298 and 008 (Table 3). These primers sequence 
the antisense strand of the opd gene. 
Com onent Quanti 
Plasmid DNA 
Primer (10 nM) 
Big Dye 
Sterile Water 
Total Volume 
250 — 300 ng 
0. 65 pL 
2. 00 pL 
Enough to bring the total volume to 7. 05PL 
705 L 
Table 2: Sequencing Reaction Conditions 
Primer 
AA98 
AA194 
AA298 
008 
Se uence 
5' CCA CGA TAT GAA CGT CG 
5' GGT TAC CGG AAC ACC GG 
5' CCA GTC ATT CGA AAC GAG G 
5' CCA GTC ACG ACG Tl G TAA AAC G 
Table 3: OPH Sequencing Primers 
Colony Screening and Its Limitations 
The proposed colony screening procedure was designed to take advantage 
of the fact that one of the products of enzymatic degradation of paraoxon, 
p-nitrophenol, has a yellow color. This allows for simple visual monitoring of the 
reaction by monitoring the appearance of p-nitrophenol's yellow color. The 
screening procedure was designed to identify variant forms of OPH with increased 
stability. Following transfer to a nitrocellulose membrane the enzyme could be 
subjected to a denaturant and then tested for activity. In this project, chemical 
denaturation with urea and guanidinium-HCL was tested, however, thermal 
denaturation is also a possibility. 
The first step in the screening process is to attach OPH to a nitrocellulose 
membrane. Freshly grown E. coli colonies expressing OPH were transferred to 
Hybond-C nitrocellulose membrane (Amersham Biosciences). The colonies were 
then lysed by placing them face up on filter paper saturated with 0. 02 M NaOH for 
30 minutes. The membrane was washed by placing it face up on filter paper 
saturated with 10mM Tris at pH 8. 2 for 1 hour. The proteins were then denatured by 
placing them on filter paper soaked in the urea or guanidinium-HCL solution. After 
the membrane was treated with denaturant, the activity of enzyme was tested by 
monitoring paraoxonase activity. The membranes were placed on 1'io agarose 
plates containing 1 mM paraoxon. Yellow color developed under colonies that 
contained active enzyme. 
Determining the correct concentration of denaturant is an essential step in 
the screening procedure. The urea solution should be just concentrated enough to 
denature the wild-type enzyme. Ideally the concentration would be determined to 
one tenth of a molar. Efforts to determine the concentration and the incubation time 
needed to exactly denature wild type OPH were unsuccessful. A potential 
explanation for this is that binding protein to a membrane stabilizes them. If the 
analysis had been performed in solution, the assay may have been more 
discriminatory. A titration of cell free extract into a dilution series of urea or 
guanidinium-HCL may have been more successful at identifying the critical 
denaturant concentration. 
Cell Free Extract Preparation 
The cell free extract used for activity assays was prepared in the following 
way. The cells were grown under the same conditions typically used for OPH 
expression. Terrific Broth (TB) media with 0. 4 '/o glycerol, 1 mM CoCIz and 50 
pg/mL ampicillin was used. Tubes containing 5 mL of TB were inoculated with 
single colonies and grown for 40 hours at 30 C. After 12-15 hours growth, an 
additional 5 pL of ampicillin (50 mg/mL stock) was added. The cells were harvested 
by centrifugation in 15 mL corex tubes at 5, 000 rpm for 15 minutes. The media was 
discarded and the cell pellet re-suspended in 500 pL of 10 mM KPO~ buffer, pH 6, 5- 
6. 9, 50 pM CoCIz. This mixture was then placed in disposable 3 mL transfer pippet 
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and sonicated for 3 x 30 sec. The cellular debris was removed by centrifuging the 
cell lysate for 15 min at maximum speed in a chilled micro-centrifuge. 
Western Blotting 
The samples used in the western blot analysis were cell free extracts 
prepared according to the previous instructions. The samples were mixed will SDS 
dye and then denatured by the boiling for 2 minutes. The samples were then loaded 
on a gel with a prestained molecular weight marker and purified OPH protein as a 
positive control. After running the SDS-PAGF gel, the protein was transferred to a 
nitrocellulose membrane. Four liters of transfer buffer was prepared by dissolving 
11. 6 g glycine, 23, 3 g Tris Base, 1. 48 g SDS and 800 mL methanol in distilled 
deionized water. The protein was transferred to the membrane overnight using 46 V 
at room temperature. 
After transferring the protein, the membrane was blocked with 1'/o gelatin. 
For this step, TBS buffer was prepared by dissolving 2. 42 g Tris Base and 29. 24 g 
NaCI in 1 liter distilled deionized water. After incubating the membrane in the 1'io 
gelatin/TBS blocking solution for 2 hours at 37, the membrane was labeled using 
rabbit primary antibody (Ab¹7000), The membrane was incubated in a solution 
containing 100 pL of Ab¹7000 and 50 mL of 1'/o gelatin/TBS buffer for 2 hours at 
37 C. Following this step, the membrane was rinsed three times with the 
gelatin/TBS buffer and labeled with the secondary antibody. Goat antirabbit 
antibody conjugated with horseradish peroxidase (HRP) was used as the secondary 
antibody. The membrane was incubated for 1. 5 hours at 37' C in a solution 
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containing 50 iiL of the secondary antibody and 50 mL of 1'io gelatin/TBS buffer. 
The membrane was then washed three times with gelatin/TBS buffer. 
Two solutions were prepared to visualize the protein using the HRP activity. 
The first is a solution containing 60 mg of 4-chloro-1-naphthol dissolved in 20 mL of 
cold methanol. The second is 60 iiL hydrogen peroxide in 100 mL of TBS buffer. 
The membrane was placed in a glass dish with the two visualization buffers. 
The dish was tipped to mix the soiution until purple bands appeared. The bands 
were allowed to develop until they could be adequately visualized then the 
membrane was removed, washed with distilled deionized water and allowed to dry. 
The dry blot was stored in a dark place. 
Measuring Paraoxon Activity 
Enzyme activity was monitored by visual detection of yellow color as 
paraoxon was hydrolyzed to diethylphosphate and p-nitropheol. One hundred pL of 
1 mM PX in 20 mM CHES buffer at pH 9 were added to each well of a 96 weil plate. 
Ten micro-liters of cell free extract were added to each well, and the time required 
for yellow color to appear was recorded. 
INeasuring Demeton-S Activity 
The activity of the variant OPH enzymes against demeton-S, an analog of the 
chemical warfare agent VX, was measured using a modified Ellman assay. The 
formation of free thiol as a result of the hydrolysis of demeton-S can be monitored 
using 2-dithiopyridone (2-dTP). The free thiol reacts with 2-dTP to form a product 
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whose absorption at 343 nm is measured with the spectrophotometer. First 2 x 
tripart buffer was prepared by mixing 7. 808 g MES, 2. 58 mL N-ethymorpholine, and 
2. 15 mL of diethanolamine in 200 mL of distilled deionized water and adjusting the 
pH to 8 using KOH. A fresh 8 mM demeton-S stock solution was then prepared by 
first mixing 2. 5 ml of 2 x tripart buffer with 6 mL of water and adjusting the pH to 8 
with KOH. Then 100 pL methanol, 0. 0022 g of 2-DTP and 20. 6 liL CHEM SERV 
demeton-S stock were mixed and added to the solution. The final volume was 
adjusted to 10 mL using distilled deionized water. The activity of the variants was 
measured using a final concentration of 2 mM demeton-S. The cuvette contained 
100 liL of cell free extract, 640 liL of 0. 5 X tripart buffer 1'lo methanol at pH 8 and 
250 pL of the 8 mM demeton-S stock. The absorbance was measured at 343 nm 
for 5 min, and the slope of the resulting curve was reported. 
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RESULTS 
Generation of Variants 
The first phase of the project was the generation of random mutations in the 
opd gene using error prone PCR. A total of 67 E. co/i colonies expressing putative 
variant forms of OPH were isolated. Eight of the variants have been sequenced to 
date (Table 4). Two of the variants, 3 and 30, contained only silent mutations that 
did not affect the amino acid sequence of the protein. These two variants express 
wild type protein and were used as positive controls in the activity assays. Based 
on the mutations found in two of the variants, 13 and 29, no protein expression is 
expected. The start codon of variant 13 was mutated to a lysine codon, indicating 
that protein should not be expressed. Variant 29 contains a missense mutation that 
converted tryptophan 69 to a stop codon. This variant should express a severely 
shortened nonfunctional form of OPH. 
Variant Position of Mutations 
Variant 3 
Variant 5 
Variant 12 
Variant 13 
One Silent Mutation: A to T change in Thr 279 
Three Mutations: Ala 68 to Val, Asp 233 to Glu, and Leu 283 to Ser 
Two Mutations: Thr 33 to Ser, and Trp 277 to Arg 
Four Mutations: Met 29 to Lys, Silent A to G Mutation in Gly 107, Thr 
147 to Ala, and lie 313 to Val 
Variant 15 
Variant 27 
Variant 29 
Variant 30 
One Mutation: His 254 to Leu 
Three Mutations: Thr 52 to Ala, Lys 82 to Met, Phe 104 to Leu 
Two Mutations: Trp 69 to stop codon, and Tyr 248 Asn 
One Silent Mutation: A to C in A 139 
Table 4: Sequence Data 
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The reaction conditions used for the mutagenesis were designed to produce 
an average of 3 mutations per 1, 000 bp. Since the opd gene is 1, 014 bp long, these 
conditions should produce an average of slightly more that 3 mutations per gene 
copy. Based on the 8 variants sequenced, the average number of changes per 
gene was 2. 1. Although the average number of mutations per gene is less than the 
expected 3, this is most likely not an indication that the mutagenesis reaction is not 
working as designed. The sample size of 8 variants is to small to be a good 
indicator of the total pool of variants, and the 8 variants sequenced were not 
selected randomly. 
Characterization of Variant Activity 
To determine the effect of the mutations on the activity of the enzyme, 
qualitative measurements of paraoxonase activity were performed. These 
measurements are summarized in Table 5. As expected variants 3 and 30, which 
contained only silent mutations, retained maximum activity against paraoxon. 
Surprisingly, variant 13, also showed paraoxonase activity in spite of the mutation in 
the start codon. This may be due to the use of the AGG codon as a start codon or 
alternatively it might be due to sample contamination. 
Variant Time To Color Development 
Variant 3 
Variant 5 
Variant 12 
Variant 13 
Variant 15 
Variant 27 
Variant 29 
Variant 30 
& 1 minute 
& 12 hours 
& 5 minutes 
1-5 minutes 
& 12 hours 
& 12 hours 
& 12 hours 
& 1 minute 
Table 5: Paraoxon Activity 
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The activity of the variants against demeton-S, a VX analog, was also 
determined. The results of this assay are given in Table 6. Although the same 
amount of cell free extract was used in all of the reactions the amount of enzyme in 
each reaction was not standardized. Differences in growth rate and the level of 
OPH expression may have led to large variations in the concentration in OPH in the 
cell free extract. These factors help to explain the difference in activity seen 
between variant 3 and 30, which are expressing the same wild type enzyme. The 
measured value for variant 29 is most likely due to experimental error, since further 
work with variant 29 showed that protein was not being expressed (data not shown). 
Variant 
Variant 3 
Variant 5 
Variant 12 
Variant 13 
Variant 15 
Variant 27 
Variant 29 
Variant 30 
Demeton ct Activity 
OD/min 
50 x 10 
2x10 
26 x10 
2x10 
3x10 
3x10 
18x10 
13x10 
Table 6: Demeton& Activity 
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DISCUSSION AND CONCLUSIONS 
The first step in understanding how mutations affect variant enzyme activities 
is to review what is currently known about OPH structure. The three important 
regions, the dimer interface, the metal binding site, and the active site, have been 
identified. OPH is a dimeric enzyme, and the residues of the dimer interface have 
been identified (Figure 3). Changing these residues might be expected to the 
affect the stability of the enzyme. The residues involved in metal binding have also 
been identified; these residues are necessary to correctly position the metal ions in 
the active site . Mutations to this region will affect the activity of the enzyme. The 9 
active site has also been characterized in some detail . The residues of the active 
site interact directly with the substrate, and mutations of this region will most likely 
affect the activity of the enzyme and influence the enzyme's specificity. 
50 MS IGTGD RINTV RGPIT ISEAG L~ QFG S FTLT ~ 
RKALA 
EII CG 
EKAVR 
I GSDV 
WP ~ 
~ cIQ 
ELVLK 
75 
GLRRA RAAGV RTIVD 100 
SLLAE VSRAA DVHIV 125 V S T SD 
AATGL 
~ 
SVE 
~ 
C I I gV 
SLATG 
gr QF 150 
ATTGK 175 
VPVTT 200 
~ 
G I RA 
AAARA 
LQI Q 
ATPFQ 
~ 
rAAS 
VCIC 
~ 
GLDSI 
SWQTR 
~FG 
AFIPL 
QRDGE QQAAI FESEG LSPSR 225 
SDDTD DLSYL TALAA RGYLI 250 
PQSA I 
ALLIK 
LAIR 
ILVSN 
275 GLEDN ASASA 
ALIDQ GYMKQ 
~ 
NIMD VQDRV 
LREKG VPQET 
300 
NPDGM 325 
LAG I T 350 RVIPF 
VTNPA RFLSP TLRAS 
~ 
v etai Binding Residues /Active Site Residues /interface Residues 9 W. . 6 8 
Figure 3: Important OPH Residues 
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The effect of the mutations found in variants 13 and 29 are obvious. These 
variants contain mutations that prevent the protein from being expressed. Although 
these variants also contain other mutations, since no protein is available the effects 
of these mutation can not be determined. No new information can be determined 
from variants 3 or 30, since these variants contain silent mutations and so express 
wild type enzyme. 
Variant 5 contains three mutations: one in the dimer interface and two in 
regions whose functions have not been determined. The first mutation, an alanine 
to valine mutation at residue 68, occurs at a critical residue in the dimer interface. 
This reside fits tightly into a pocket in the other subunit (Figure 4). The amount of 
buried surface area for this alanine residue increases from 25 k in the monomer 
form to 98'lo in the dimer . The increased size of the valine residue compared to the 
alanine may have destabilized the enzyme's structure leading to the low activity 
seen for this variant. The second mutation, an aspartic acid to glutamic acid 
mutation at 233, is on the surface of the enzyme and involves very similar amino 
acids. For these reasons, this mutation would not be expected to significantly affect 
the enzyme's activity. The third mutation, a leucine to serine substitution at 283, 
also occurs at the enzyme's surface and therefore is also not likely to affect the 
enzyme's activity. 
Figure 4: Variant 5 The position of the Ala 68 to Val mutation is shown in light 
blue. The positions of the Asp 233 to Glu, and Leu 283 to Ser mutations are shown 
in dark red. The substrate is shown in black and the two zinc ions in orange. 
(Created using Protein Explorer, http: //proteinexplorer. org) 
Variant 12 contains two mutations that decreased the enzyme's activity. The 
first, a threonine to serine mutation, occurred at amino acid 33. This residue is part 
of an unstructured leader region, located only 4 residues form the N-terminus. 
Mutations in this region probably do not effect the protein's activity. The second 
mutation is a tryptophan to arginine mutation at position 277. Although this mutation 
is on the surface of the protein it may have some affect on the protein's stability. 
The mutation changed position 277 from a polar tyrosine to a positively charged 
arginine. This positions two positively charged residues very close together and 
may destabilize the protein (Figure 5). 
18 
rvlDL 
Figure 5: Variant 12 Trp 277 is shown in dark red and the neighboring Arg 331 is 
shown in blue. Thr 33 is not shown. The substrate is shown in black and the two 
zinc ions in orange. (Created using Protein Explorer, http: //proteinexplorer. org) 
Only one mutation is present in variant 15, but this mutation severely 
disrupted enzyme activity. The sole mutation is a histidine to leucine mutation at 
position 254 (Figure 6). The histidine residue at position 254 is important in 
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providing stability to the active site. There are three histidine residues in the active 
site, His 230, His 254 and His 257, which are closely spaced and stabilized by Van 
der Waals interactions . Substituting a leucine at position 254 may disrupt this 
interaction, then destroying the enzyme's activity. 
i-&ID L 
Figure 6: Variant 15 The position of the His 254 to Leu mutation is shown in light 
pink. His 230 is shown in green and His 257 is shown in magenta. The substrate is 
shown in black and the two zinc ions in orange. 
(Created using Protein Explorer, http:I/proteinexplorer. org) 
Variant 27 contains three mutations: one in the dimer interface, phenylalanine 
104 to leucine, and two in regions of unknown function, threonine 52 to alanine and 
lysine 82 to methionine (Figure 7). These mutations obliterate the enzyme's activity. 
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Figure 7: Variant 27 The position of the Phe 104 to Leu mutation is shown in light 
blue. The Thr 52 to Ala, and Lys 82 to Met mutations are shown in dark red. 
(Created using Protein Explorer, http:I/proteinexplorer. org) 
The aim of this project was to identify new regions of the OPH structure that 
are important to enzyme function. A pool of 67 variant enzymes was created using 
error prone PCR. Eight of these variants were sequenced, and their activities were 
examined. From these eight, four of the variants were further analyzed. Of these 
four, three contained mutations in one of the three previously identified regions, 
reaffirming the importance of these regions. Variant 12 contained two mutations 
and may have identified a new region important for enzyme activity. 
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